Articles

Science fiction is quickly becoming science fact as a team of German scientists found that a small, lab-grown brain cell cluster that developed fundamental eye structures.

Single-use cataract surgery comes with several safety and quality attributes.

Fluorescence lifetime imaging ophthalmoscopy may be useful to monitor the progression of AMD as well as the effectiveness of treatment approaches.

The EURETINA 2021 Virtual Meeting is scheduled for September 9 to 12, 2021, and retina specialists are eager to see the showcase of cutting-edge scientific developments.

Long-term treatment helps chronic, vision-threatening disease.

The versatile technique comes with short learning curve and combines well with MIGS.

Ophthalmologists face challenges of drug delivery for retinal diseases.

In response to a previously published article, three ophthalmologists present their views on intravitreal pharmacotherapy injections.

RGX-314 viewed by investigators as a therapeutic option for exudative AMD.

OCULUS has combined efforts with International Myopia Institute to raise awareness of myopia and drive scientific advancements to prevent sight-threatening complications and blindness, which may arise as a result.

With at least 24 inherited retinal disease (IRD) clinical trials ongoing in the United States, and additional studies of stem cell therapy in several IRD indications, hope is on the horizon for many patients.

Study of subjects with rare inherited form of AD shows increased retinal capillary perfusion during the presymptomatic stage.

The U.S. FDA granted orphan drug designation to ADX-2191, methotrexate for intravitreal injection, as treatment for retinitis pigmentosa.

If approved, Genentech’s treatment of faricimab will be the first and only medicine targeting two distinct pathways, Ang-2 and VEGF-A, that often cause retinal diseases that may cause vision loss.

Why investigators are recognising AMD as a disease spectrum rather than a single entity.

Retrospective review highlights the sustained efficacy of combination procedure.

The proportion of eyes that developed PDR or centre-involving DMO was lower with periodic aflibercept treatments compared with sham treatment through the 2-year point.

While operating on a patient with chronic uveitis presents some challenges, there are a few pearls that may increase success.

Ophthalmologists should consider numerous options for treating individual glaucoma patients, including non-medical interventions.

Landmark randomised controlled trials have advanced the understanding and treatment of glaucoma.

The glaucoma treatment company rebrands to align more closely with goals and direction of the company.

A new MRCS ophthalmology examination will be offered to ICO College Members beginning in 2022.

Investigators found that 56.4% of Horner’s syndrome cases resulted from a dangerous cause.

In endophthalmitis, the systemic anti-infective treatment specific to the infectious agent should always be used.

According to researchers, fluorescence lifetime imaging ophthalmoscopy reveals disease-related patterns not visible with other imaging modalities.

A recent retrospective analysis of LASIK and PRK patients helped to provide insights into patient satisfaction postoperatively. Such analyses might lead to improved patient outcomes.

One ophthalmologist provides her pearls for managing cases of prolapsed iris and reconstructing it following trauma.

Surgeons now have an increasing range of technologies for modulating phaco power to achieve the best results in cataract surgery.

Minimally invasive glaucoma surgery (MIGS) is appealing to glaucoma patients and surgeons; however, it should not be adopted without further high-quality research and careful reporting. Selection of the appropriate treatment for individual patients must be evidence based.

Orthokeratology and multifocal contact lenses provide clinically meaningful reductions in progression of myopia, research shows, but some questions, such as the ideal treatment duration, remain unanswered.